CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The NDA is supported by data from a clinical trial that compared the absorption and efficacy of the nasal treatment with oral and IV bumetanide in 68 healthy adults.

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

The new FDA approval means people can use the nasal spray as-is to treat depression. Meaning, there's no need to take an oral antidepressant with it. That said, Spravato is a tightly controlled ...

The Food and Drug Administration (FDA) approved Johnson & Johnson's ketamine-derived nasal spray to help millions ... There has been a growing use of using ketamine – described as a ...

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...

and Endo USA, in Malvern, Pa with FDA-approved injectable epinephrine products for intravenous use. Epinephrine nasal spray is usually given at the first sign of an allergic reaction. BPI Labs and ...

The U.S. Food and Drug Administration has expanded its approval of Spravato, an antidepressant nasal spray. The drug is now cleared for use as a standalone treatment for depression. Spravato is ...